Where Tech Meets Bio

Where Tech Meets Bio

Home
Podcast
Archive
About
Weekly Tech+Bio Highlights #44: New 9.8 Billion Protein Dataset Built for Generative Biology
Rethinking IP in the Age of AI Protein Design, Compressing Medical Images With Clinical Signal Intact, & Where AI in Drug R&D Is (and Isn’t) Gaining…
 • 
BiopharmaTrend
 and 
Roman Kasianov
1
Weekly Tech+Bio Highlights #43: New Foundation Model from MIT & Recursion
Also: Spatial Biology Means Terabyte-Scale Files, A Visual Guide to Genome Editors, Biotech VC Enters Quieter Phase, & Why AI Hallucinations May Be a…
 • 
BiopharmaTrend
 and 
Roman Kasianov
1
17 More Biomedical AI Foundation Models
MIT & Recursion's Boltz-2 just launched—here’s a fresh scan of 15+ new models spanning chemistry, oncology, trials, and clinical workflows
 • 
BiopharmaTrend
 and 
Illia Terpylo
Most Popular
View all
Ex-NASA Expert Unveils Everything You Need to Know About Brain-Computer Interfaces
 • Andrii Buvailo
The '4th Wave' of AI Drug Discovery is Here, According to This Report
 • Andrii Buvailo
11 Biopharma Trends to Watch in 2024
 • Andrii Buvailo
13 Foundation Models: Startups, Industry Updates and the Nobel Prize
 • BiopharmaTrend
1
12 Startups in the Digital Twin Healthcare Ecosystem: From Virtual Organs to Optimized Trials
 • BiopharmaTrend
14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools
 • BiopharmaTrend and Illia Terpylo
Weekly Tech+Bio Highlights #42: Proteins, the Universe, and Everything
Neuralink's $650M Raise, Interactive Map of Digital-Pathology Deals, ASCO AI Highlights, and a 10-Year Quest to Map Cell Behavior
 • 
BiopharmaTrend
 and 
Roman Kasianov
14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools
How a 2024’s Nobel in Chemistry, 200 million predicted structures, and $1 billion startup round shape the new fold of protein design
 • 
BiopharmaTrend
 and 
Illia Terpylo
Weekly Tech+Bio Highlights #41: Fortnight Overview
AI Benchmarks, Models, & Gene Editing Startups—$700M+ in New Biotech Funding
 • 
BiopharmaTrend
 and 
Roman Kasianov
AI Meets Clinical Trials: Recent Policy Shifts & Companies to Watch
Today, clinical trials are longer and more data-heavy than a decade ago. At a time of regulatory rethinking, we trace how AI is beginning to orchestrate…
 • 
BiopharmaTrend
Weekly Tech+Bio Highlights #40: FDA Sets Deadline for Internal AI Rollout
Also: Foundation Models & Drug‑Discovery Economics, Structuring Meaning for AI with Ontologies, & Emerging Startups
 • 
Roman Kasianov
 and 
BiopharmaTrend
Weekly Tech+Bio Highlights #39: Towards Human-Based Models
Also: AI News, NIH's Policy Shift & What Clinical AI Struggles With
 • 
Roman Kasianov
 and 
BiopharmaTrend
The Infrastructure Layer: Platforms Powering Human-Relevant Drug Development
Infrastructure for large-scale biomedical data—from multi-omics to EHRs—is converging with a growing policy and business case for data-native drug…
 • 
BiopharmaTrend
Weekly Tech+Bio Highlights #38: Predictive Models & Benchmarks
Also: Two-Hour Zebrafish Brain Benchmark, BCI Patent Landscape, & Steering Complex Structure Predictions
 • 
Roman Kasianov
 and 
BiopharmaTrend
Weekly Tech+Bio Highlights #37: Turning Cells Into Language
Also: Who Runs the Tools in AI–Pharma Deals, Four Challenges at the AI-Biology Interface & Industry Highlights
 • 
Roman Kasianov
 and 
BiopharmaTrend
Where Tech Meets Bio
Where Tech Meets Bio
What does the future hold for us in the “century of biotech“?
Recommendations
View all 6
Noahpinion
Noahpinion
Noah Smith
People vs Algorithms
People vs Algorithms
Troy Young
Special Competitive Studies Project
Special Competitive Studies Project
SCSP
AI Supremacy
AI Supremacy
Michael Spencer
The Algorithmic Bridge
The Algorithmic Bridge
Alberto Romero

Where Tech Meets Bio

AboutArchiveRecommendationsSitemap
© 2025 BiopharmaTrend (BPT Analytics Ltd)
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture